Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer

BACKGROUND: Resistance to endocrine therapy in breast cancer is associated with activation of the mammalian target of rapamycin (mTOR) intracellular signaling pathway. In early studies, the mTOR inhibitor everolimus added to endocrine therapy showed antitumor activity. METHODS: In this phase 3, rand...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:N Engl J Med
Main Authors: Baselga, José, Campone, Mario, Piccart, Martine, Burris, Howard A., Rugo, Hope S., Sahmoud, Tarek, Noguchi, Shinzaburo, Gnant, Michael, Pritchard, Kathleen I., Lebrun, Fabienne, Beck, J. Thaddeus, Ito, Yoshinori, Yardley, Denise, Deleu, Ines, Perez, Alejandra, Bachelot, Thomas, Vittori, Luc, Xu, Zhiying, Mukhopadhyay, Pabak, Lebwohl, David, Hortobagyi, Gabriel N.
Formato: Artigo
Idioma:Inglês
Publicado em: 2011
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5705195/
https://ncbi.nlm.nih.gov/pubmed/22149876
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa1109653
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados